December 15th, 2015

Theralase Appoints Director of Clinical Education / Training and Clinic Director

TORONTO, ON / ACCESSWIRE / November 24, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTC: TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has appointed Dr. Elizabeth Angelevski as the Director of Clinical Education / Training and Dr. Alex Peplow as the Clinic Director of Theralase.

Dr. Angelevski graduated from Canadian Memorial Chiropractic College ("CMCC") in 2009 and from McMaster University with a Bachelor of Science in Kinesiology (Honours) in 2005. She is a licensed chiropractor with an avid interest in sports injuries and rehabilitation.

Dr. Angelevski will be responsible for:

- Providing clinical overview to the marketing program for the next generation therapeutic laser
- Training all healthcare practitioners on the safe and effective use of the next generation therapeutic laser
- General management of the Theralase clinic

Dr. Peplow graduated from York University in 2008 with a degree in Kinesiology (Honours) and in 2013 from CMCC as a Doctor of Chiropractic. Dr. Peplow is certified in Active Release Techniques ("ART(R)") and Graston Techniques(R) and uses his training to treat patients with numerous nerve, muscle and joint conditions, as well as athletes who compete in: hockey, boxing, cycling and golf.

Dr. Peplow will be responsible for:

- Managing the day to day operations of the Theralase clinic
- Treating patients in the Theralase clinic

Both Dr. Angelevski and Dr. Peplow will utilize the next generation therapeutic laser in the clinic working in conjunction with Theralase's Key Opinion Leaders ("KOLs") to optimize the technology, provide continuing feedback and support to the ever growing customer base in Canada, the US and internationally.

Roger Dumoulin-White, President and CEO, Theralase stated that, "I am delighted that Liz and Alex have decided to join the Theralase team in their respective capacities. Both are high energy healthcare professionals dedicated to: helping patients eliminate their pain and return to healthy lifestyles, providing world class training to healthcare practitioners and helping to build the Theralase brand internationally. Please join me in welcoming them to our family."

About Theralase Technologies Inc.

Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (OTC: TLTFF) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.